<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04792008</url>
  </required_header>
  <id_info>
    <org_study_id>YQ23-19001</org_study_id>
    <nct_id>NCT04792008</nct_id>
  </id_info>
  <brief_title>YQ23 Study in Patients With Critical Limb Ischaemia</brief_title>
  <acronym>YAN</acronym>
  <official_title>A Randomised, Double-Blind, Phase 1b/2a, Placebo-Controlled, Single Dose Study to Evaluate Safety, Tolerability, and Efficacy of YQ23 in Adult Patients With Critical Limb Ischaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New Beta Innovation Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New Beta Innovation Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an early phase study to assess how safe and tolerable is the new study drug YQ23 and&#xD;
      to compare the effectiveness of YQ23 against normal saline to treat critical limb ischaemia.&#xD;
      The study also aims to understand how it affects the body and an optional substudy to assess&#xD;
      how the human body takes up, breaks down, and clears the study drug.&#xD;
&#xD;
      Eligible patients will be randomised to have a 2:1 chance to receive a single, intravenous,&#xD;
      fixed dose of YQ23 or normal saline. Neither the patient nor the study site will know which&#xD;
      treatment has been given.&#xD;
&#xD;
      On the day of YQ23 administration, patients will be asked to stay in the study site for 3&#xD;
      days for safety observation. After discharge, they will be required to visit the study clinic&#xD;
      for 3 times in a year to continue safety monitoring and assessment of treatment effect.&#xD;
&#xD;
      Each subject's participation will be about 13 months after signing the informed consent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2a, randomised, double-blind, placebo-controlled study to evaluate the&#xD;
      safety, tolerability, and efficacy of an investigational product, YQ23, in patients with&#xD;
      Critical Limb Ischaemia (CLI) during a follow-up period of 12 months.&#xD;
&#xD;
      Fifty-one patients are planned for enrolment. The study consists of a screening period (up to&#xD;
      28 days), a double-blind treatment period, and a follow-up (12 months). Prior to&#xD;
      randomisation, patients diagnosed with CLI will be stratified into:&#xD;
&#xD;
        -  Group of patients in whom revascularisation is not planned&#xD;
&#xD;
        -  Group of patients with planned revascularisation&#xD;
&#xD;
      Within each group, patients will be randomised in a 2:1 ratio to receive single intravenous&#xD;
      infusion of YQ23 120 mg/kg and normal saline, respectively at the study site.&#xD;
&#xD;
      On the day of YQ23 administration, the patient will be admitted to the study site on Day 1&#xD;
      and will be discharged on Day 3. The total duration of participation in the study for each&#xD;
      patient is approximately 13 months. Data on the study endpoints will be collected from&#xD;
      baseline (pre-dose on Day 1), Day 3, Month 1, 6 and up to 12 months after study treatment&#xD;
      infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single IV dose of YQ23 - adverse and serious adverse events</measure>
    <time_frame>From the time of signing informed consent through study completion, a duration of 13 months.</time_frame>
    <description>Incidence of adverse events and serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV dose of YQ23 - abnormal laboratory values</measure>
    <time_frame>From the time of signing informed consent through study completion, a duration of 13 months.</time_frame>
    <description>Number of participants with a change in laboratory values of haematology, chemistry or urinalysis which is of clinical significance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV dose of YQ23 - 12 lead electrocardiogram (ECG)</measure>
    <time_frame>From the time of signing informed consent through study completion, a duration of 13 months.</time_frame>
    <description>Number of participants with a change in 12-lead ECG measurements which is of clinical significance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV dose of YQ23 - vital signs</measure>
    <time_frame>From the time of signing informed consent through study completion, a duration of 13 months.</time_frame>
    <description>Number of participants with a change in vital signs of blood pressure, pulse rate, respiratory rate or oral temperature which is of clinical significance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV dose of YQ23 - physical examinations</measure>
    <time_frame>From the time of signing informed consent through study completion, a duration of 13 months.</time_frame>
    <description>Number of participants with a change in physical examination findings which is of clinical significance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of single IV dose of YQ23 - major adverse limb events (MALE)</measure>
    <time_frame>From pre-dose to Month 1</time_frame>
    <description>The incidence of MALE of interest. MALE include amputation (transtibial or above) or any major vascular intervention in the index limb</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - all cause mortality</measure>
    <time_frame>From the time of signing informed consent to Month 12</time_frame>
    <description>Incidence rate of all deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - amputation free survival</measure>
    <time_frame>From pre-dose to Month 12</time_frame>
    <description>Incidence rate of all amputations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - MALE of interest</measure>
    <time_frame>At month 6 and 12</time_frame>
    <description>Incidence of MALE of interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - Rutherford classification</measure>
    <time_frame>From pre-dose, Month 1, 6 and 12</time_frame>
    <description>Change in Rutherford classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - visual analogue pain scale</measure>
    <time_frame>From pre-dose, Month 1, 6 and 12</time_frame>
    <description>Change in visual analogue pain scale in a one to ten scale - one reported as no pain while 10 as the most intense pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - wound healing in size</measure>
    <time_frame>From pre-dose, Month 1, 6 and 12</time_frame>
    <description>Change in size as measured by length x width x depth in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - wound healing by transparent film</measure>
    <time_frame>From pre-dose, Month 1, 6 and 12</time_frame>
    <description>Change in size as measured by the number of grids in a wound tracing film</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - wound healing 100%</measure>
    <time_frame>From pre-dose, Month 1, 6 and 12</time_frame>
    <description>Number of participants to achieve 100% epithelialization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - wound healing by Wound, Ischemia, and Foot Infection (WIFI) classification system</measure>
    <time_frame>From pre-dose, Month 1, 6 and 12</time_frame>
    <description>Change in the grading under the WIFI classification system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - transcutaneous oxygen pressure</measure>
    <time_frame>From pre-dose, 2 hours post-dose, Month 1, 6 and 12</time_frame>
    <description>Change in transcutaneous oxygen pressure (TcPO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - quality of life score</measure>
    <time_frame>From pre-dose, Month 1, 6 and 12</time_frame>
    <description>Change in EuroQol -5 Dimension (EQ-5D) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - ankle brachial index (ABI)</measure>
    <time_frame>From pre-dose, Month 1, 6 and 12</time_frame>
    <description>Change in ABI, a ratio of systolic blood pressure at the ankle to that in the arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of single dose YQ23 as compared to placebo - toe brachial index (TBI)</measure>
    <time_frame>From pre-dose, Month 1, 6 and 12</time_frame>
    <description>Change in TBI, a ratio of systolic blood pressure at the toe to that in the arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An optional substudy to assess the pharmacokinetics of YQ23 - maximum observed concentration (Cmax)</measure>
    <time_frame>From pre-dose, immediately after end of infusion, 0.25, 0.5, 1, 2, 6, 18 (+/-6) and 48 hours post end of infusion</time_frame>
    <description>Plasma level of YQ23 will be serially evaluated following dosing of the study drug to determine the Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An optional substudy to assess the pharmacokinetics of YQ23 - time to Cmax</measure>
    <time_frame>From pre-dose, immediately after end of infusion, 0.25, 0.5, 1, 2, 6, 18 (+/-6) and 48 hours post end of infusion</time_frame>
    <description>Plasma level of YQ23 will be serially evaluated following dosing of the study drug to determine the time corresponding to occurrence of the Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An optional substudy to assess the pharmacokinetics of YQ23 - Area under the curve (0 to last)</measure>
    <time_frame>From pre-dose, immediately after end of infusion, 0.25, 0.5, 1, 2, 6, 18 (+/-6) and 48 hours post end of infusion</time_frame>
    <description>Plasma level of YQ23 will be serially evaluated following dosing of the study drug to determine the area under the plasma concentration-time curve (AUC) - AUC from time 0 to the last measurable time point (AUClast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An optional substudy to assess the pharmacokinetics of YQ23 - Area under the curve (0 to infinity)</measure>
    <time_frame>From pre-dose, immediately after end of infusion, 0.25, 0.5, 1, 2, 6, 18 (+/-6) and 48 hours post end of infusion</time_frame>
    <description>Plasma level of YQ23 will be serially evaluated following dosing of the study drug to determine the area under the plasma concentration-time curve (AUC) - AUC from time 0 extrapolated to infinity (AUCinf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An optional substudy to assess the pharmacokinetics of YQ23 - terminal elimination half-life (t1/2)</measure>
    <time_frame>From pre-dose, immediately after end of infusion, 0.25, 0.5, 1, 2, 6, 18 (+/-6) and 48 hours post end of infusion</time_frame>
    <description>Plasma level of YQ23 will be serially evaluated following dosing of the study drug to determine the t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An optional substudy to assess the pharmacokinetics of YQ23 - total clearance (CL)</measure>
    <time_frame>From pre-dose, immediately after end of infusion, 0.25, 0.5, 1, 2, 6, 18 (+/- 6) and 48 hours post end of infusion</time_frame>
    <description>Plasma level of YQ23 will be serially evaluated following dosing of the study drug to determine the CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An optional substudy to assess the pharmacokinetics of YQ23 - volume of distribution during terminal phase (Vz)</measure>
    <time_frame>From pre-dose, immediately after end of infusion, 0.25, 0.5, 1, 2, 6, 18 (+/- 6) and 48 hours post end of infusion</time_frame>
    <description>Plasma level of YQ23 will be serially evaluated following dosing of the study drug to determine the Vz</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <arm_group>
    <arm_group_label>YQ23 Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two-third of randomized patients will receive YQ23 as active treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Single dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One-third of randomized patients will receive matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>YQ23</intervention_name>
    <description>Single dose of 120 mg/kg YQ23 via intravenous route will be evaluated</description>
    <arm_group_label>YQ23 Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <description>Single dose of 0.9% normal saline via intravenous route as matching placebo</description>
    <arm_group_label>Placebo Single dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of CLI (Rutherford Classification stage 4, 5 or 6) including at least one of&#xD;
             the following:&#xD;
&#xD;
               1. resting ankle systolic pressure (either dorsalis pedis or posterior tibial&#xD;
                  artery) &lt;=70 mmHg in affected limb&#xD;
&#xD;
               2. resting toe systolic pressure &lt;=50 mmHg in affected limb&#xD;
&#xD;
               3. TcPO2 &lt;=30 mmHg&#xD;
&#xD;
          -  One of the following clinical presentations:&#xD;
&#xD;
               1. pain at rest&#xD;
&#xD;
               2. ischaemic ulcer, and/or focal gangrene for at least 2 weeks&#xD;
&#xD;
          -  Diagnosis of severe lower extremity peripheral artery occlusive disease as evidenced&#xD;
             by either:&#xD;
&#xD;
               1. Documented significant stenosis (&gt;=75%) of &gt;=1 of the following arteries:&#xD;
                  superficial femoral, popliteal, and infra-popliteal arteries, as assessed by&#xD;
                  imaging test, or&#xD;
&#xD;
               2. ABI &lt;=0.80 or TBI &lt;=0.60 of the index leg (in the event of non-compressible ankle&#xD;
                  arteries) for patients without a prior history of limb revascularization on the&#xD;
                  index leg, or an ABI &lt;=0.85 or TBI &lt;=0.65 of the index leg (in the event of&#xD;
                  non-compressible ankle arteries) for patients with a prior history of limb&#xD;
                  revascularization on the index leg.&#xD;
&#xD;
          -  Contraceptive use&#xD;
&#xD;
               1. Male patients and their female spouses/partners who are of childbearing potential&#xD;
                  must agree to use a high effective contraception consisting of two forms of birth&#xD;
                  control detailed in the protocol during the treatment period and for at least 6&#xD;
                  days after the dose of the study treatment and refrain from donating sperm during&#xD;
                  this period&#xD;
&#xD;
               2. A female patient is eligible if she is not pregnant, not breastfeeding, and at&#xD;
                  least on of the following conditions applies: (i) not a woman of childbearing&#xD;
                  potential (WOCBP), (ii) A WOCBP who agrees to follow the contraceptive guidance&#xD;
                  in the protocol during the treatment period and for at least 6 days after the&#xD;
                  dose of study treatment and refrain from donating ova during this period&#xD;
&#xD;
          -  Patient is capable of giving signed informed consent which includes compliance with&#xD;
             the requirements and restrictions listed in the informed consent and the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have undergone successful revascularisation on the index leg within 4&#xD;
             weeks of the qualifying event&#xD;
&#xD;
          -  Patients with estimated life expectancy &lt;12 months&#xD;
&#xD;
          -  Acute limb ischaemia due to thromboembolism within 2 weeks of the qualifying event&#xD;
&#xD;
          -  Recent myocardial infarction within 30 calendar days prior to signing informed consent&#xD;
&#xD;
          -  Recent stroke within 30 calendar days prior to signing informed consent&#xD;
&#xD;
          -  Known history of severe congestive heart failure as determined through review of&#xD;
             medical history&#xD;
&#xD;
          -  Haemoglobin &lt;8 g/dL, albumin &lt;3 g/dL or other clinically significant abnormalities in&#xD;
             the laboratory tests at screening&#xD;
&#xD;
          -  Unwilling to complete follow-up evaluation&#xD;
&#xD;
          -  Uncontrolled arterial hypertension with systolic blood pressure (SBP) &gt;180 mmHg and/or&#xD;
             diastolic blood pressure (DBP) &gt;100 mmHg at screening&#xD;
&#xD;
          -  Patients with history of long QT syndrome or whose QTc (calculated according to Bazett&#xD;
             formula QTc = QT/ âˆšRR) &gt;470 ms at screening&#xD;
&#xD;
          -  Patients with severe left ventricular dysfunction of &lt;40% at screening&#xD;
&#xD;
          -  Patients with clinically significant abnormalities in ECG parameters (other than QTc)&#xD;
             or in the physical examination at screening that might comprise patient safety&#xD;
&#xD;
          -  History of coagulopathy&#xD;
&#xD;
          -  Patients having significant renal impairment with estimated glomerular filtration rate&#xD;
             (eGFR) &lt;30 mL/min/1.73 m2 as determined by the 4-variable Modification of Diet in&#xD;
             Renal Disease (MDRD) equation at Screening, except those patients who are on&#xD;
             continuous ambulatory peritoneal dialysis(CAPD) or hemodialysis (HD)&#xD;
&#xD;
          -  Significant liver impairment (abnormal Liver Function Tests &gt;3 x upper limit of&#xD;
             normal)&#xD;
&#xD;
          -  Patients with active Hepatitis B infection (HBsAg positive and HBeAg positive) at&#xD;
             screening&#xD;
&#xD;
          -  Patient with a positive test for Hepatitis C virus antibody (anti-HCV) at screening&#xD;
&#xD;
          -  Patient with known history of infection with human immunodeficiency virus (HIV) or any&#xD;
             other active or chronic infection&#xD;
&#xD;
          -  Patients with evidence of uncontrolled hypo- or hyperthyroidism&#xD;
&#xD;
          -  History active malignancy (as determined through review of medical history), excluding&#xD;
             local skin cancer (basal or squamous cell carcinoma)&#xD;
&#xD;
          -  Patients unable to provide informed consent&#xD;
&#xD;
          -  Known allergy to bovine products&#xD;
&#xD;
          -  Receipt of bovine haemoglobin-based oxygen carrier (HBOC) or other HBOC in the past&#xD;
&#xD;
          -  Use of an investigational drug or treatment within 12 months prior to signing informed&#xD;
             consent; concurrent participation in any other investigational protocol&#xD;
&#xD;
          -  Pregnancy and breastfeeding, as well as unwillingness to use effective methods&#xD;
             contraception for women of childbearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Billy Lau</last_name>
    <role>Study Director</role>
    <affiliation>New Beta Innovation Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evonne Bi</last_name>
    <phone>+852 2133 8892</phone>
    <email>evonne.bi@newbetainnovation.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zita Lee</last_name>
    <phone>+852 2133 7604</phone>
    <email>zita.lee@newbetainnovation.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Sha Tin</city>
        <state>New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Xu</last_name>
      <email>danielxu@cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Bryan Yan, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Venus Ho</last_name>
      <email>vslho@hku.hk</email>
    </contact>
    <investigator>
      <last_name>David Siu, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

